Pure Global

A Phase 1b Study to Evaluate the Safety of XEN-101 - Trial NCT06417697

Access comprehensive clinical trial information for NCT06417697 through Pure Global AI's free database. This Phase 1 trial is sponsored by Xeno Biosciences and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06417697
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06417697
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Phase 1b Study to Evaluate the Safety of XEN-101
A Phase 1b, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Effects of XEN-101 on Safety, Tolerability, and Pharmacodynamics in Subjects With Obesity

Study Focus

Obesity

XEN-101

Interventional

drug

Sponsor & Location

Xeno Biosciences

Timeline & Enrollment

Phase 1

Jun 01, 2024

Sep 01, 2024

32 participants

Primary Outcome

Incidence of treatment emergent adverse events (safety and tolerability),Effect on body weight

Summary

This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity

ICD-10 Classifications

Obesity
Other obesity
Obesity, unspecified
Obesity due to excess calories
Obesity and other hyperalimentation

Data Source

ClinicalTrials.gov

NCT06417697

Non-Device Trial